The Formulation Is Part of the Medicine

This week’s research lands in three very different organs—the brain, liver, and heart—but the same lesson keeps surfacing: a plausible pathway is only the beginning. The molecule, formulation, exposure window, endpoint, and patient population can each decide whether a clean mechanism turns into useful medicine. That is why “GLP-1” or “thymosin beta-4” is not a sufficiently precise description of an intervention.

We’re looking at DD01, a liver-targeted GLP-1/glucagon dual agonist that moved MRI-measured liver fat quickly; exenatide, lixisenatide, liraglutide, and NLY01 in a disputed Parkinson’s evidence base; and PEG-rTβ4, an engineered thymosin beta-4 candidate tested after myocardial infarction in rats. Semaglutide, tirzepatide, and retail TB-500 appear around the edges of these stories, but none can simply be substituted for the compound that was actually studied.

The practical theme is evidence matching. A surrogate marker is not a clinical outcome. A pooled average is not stronger than its component trials. A longer-lasting recombinant construct is not equivalent to a similarly named research vial. If you are evaluating a protocol, those distinctions matter more than the excitement attached to a drug class.

DD01 clears liver fat fast—and now has to prove that matters

The clearest efficacy number of the week came from a randomized, double-blind phase 2 trial of DD01 in 67 adults with obesity or overweight plus MASLD or MASH. After 12 weeks, 25 of 33 people receiving once-weekly 40 mg DD01 achieved at least a 30% relative reduction in liver fat by MRI-PDFF. Four of 34 people on placebo did the same. That is 76% versus 12%, an adjusted relative risk of 6.3, and a separation large enough to take seriously even in a small study.

Mechanistically, DD01 combines GLP-1 signaling with glucagon-receptor activity. GLP-1 can reduce appetite and support glucose control; balanced glucagon signaling may increase energy expenditure and hepatic fat oxidation. The liver-targeting claim is important because the goal is not merely to reduce the delivery of fat to the liver through weight loss, but to alter hepatic metabolism more directly. The 30% MRI-PDFF threshold is associated with better odds of histologic improvement, yet it remains a surrogate. It does not prove that inflammation resolved, fibrosis regressed, or future cirrhosis risk fell.

Tolerability is the immediate constraint. Nausea affected 55% of DD01 recipients, vomiting 30%, and diarrhea 27%; four of 33 treated participants discontinued because of adverse events. A slower titration or different dose may improve that profile, but the published regimen used only two weeks of escalation, and future optimization is not current evidence. The full 48-week analysis needs to connect rapid fat loss to fibrosis, durability, metabolic outcomes, and treatment persistence. DD01 is investigational and is not a self-directed alternative to approved care.

Read the full analysis →

GLP-1 drugs and Parkinson’s: one class, incompatible conclusions

A July meta-analysis pooled six studies represented by eight publications and 850 participants receiving exenatide, lixisenatide, liraglutide, or NLY01. Motor scores modestly favored treatment immediately after therapy, with a standardized mean difference of −0.21, and at follow-up, at −0.32. Mood also favored treatment, while cognition became significant only at follow-up. Those numbers preserve a neurological hypothesis. They do not establish that GLP-1 drugs slow Parkinson’s disease.

The signal changes with the analysis. Immediate improvement appeared in the ON-medication motor state but not the OFF state; at follow-up, that pattern reversed. Activities of daily living, walking, quality of life, sleep, dyskinesia, and levodopa dose did not significantly improve. Heterogeneity for the post-treatment motor result reached 70.2%, meaning the pooled average masks substantial disagreement among trials. Other 2026 reviews restricted their main analysis to four high-quality double-blind trials with 667 participants and found no significant motor benefit in either medication state.

Individual trials explain why caution wins. Lixisenatide produced a 3.08-point between-group advantage on MDS-UPDRS Part III after 12 months in the 156-person LIXIPARK phase 2 study, but nausea affected 46% and vomiting 13%. NLY01 missed its primary endpoint in 255 untreated participants. Most importantly, weekly exenatide failed in the 194-person, 96-week Exenatide-PD3 phase 3 trial: the adjusted treatment effect was 0.92 points, the confidence interval crossed zero, and p was 0.47. None of these trials tested semaglutide or tirzepatide. Different half-lives, brain exposure, and receptor profiles make a class-wide extrapolation premature.

Read the full analysis →

PEGylated thymosin beta-4 shows why exposure can beat more dose

Thymosin beta-4 has a compelling repair résumé on paper: it binds actin, supports cell migration, influences apoptosis, and promotes blood-vessel growth. Its drug-development problem is pharmacokinetic. In an earlier phase 1 study, increasing intravenous synthetic thymosin beta-4 from 42 to 1,260 milligrams only stretched the half-life from about 0.95 to 2.1 hours. More drug did not solve rapid clearance.

The new study engineered recombinant Tβ4 with a specific cysteine attachment site and added PEG2000. In infarcted rats, PEG-rTβ4 lasted about four hours versus one hour for unmodified rTβ4. Animals received the equivalent of 2 mg/kg intravenously every three days for four weeks. The PEGylated version improved left-ventricular ejection fraction, reduced border-zone fibrosis, increased vascular markers, and shifted Akt, Bcl-2, and caspase signaling toward cell survival more consistently than the unmodified peptide. Blocking Akt weakened several effects, which supports—but does not prove—the proposed mechanism.

The translational gap is still wide. The main animal groups contained six rats, some tissue analyses used three samples, and PEG-rTβ4 itself has never been tested in humans. A separate 96-patient trial of recombinant human Tβ4 after STEMI did not significantly reduce infarct area overall, although a 43-person subgroup treated within eight hours of PCI had a better 90-day signal. Timing may matter, but subgroup results need prospective confirmation. Retail TB-500 is not this sterile recombinant construct, and it is not the site-specific PEGylated candidate. This paper is a formulation study, not a heart-attack protocol.

Read the full analysis →

What to watch next

The next useful DD01 result is the 48-week dataset, especially biopsy or fibrosis measures and discontinuation rates. Parkinson’s research needs larger, agent-specific trials that predefine ON/OFF medication states and distinguish symptomatic relief from disease modification. PEG-rTβ4 first needs replication in a larger animal model with realistic reperfusion, immune monitoring, and longer follow-up before a phase 1 program is persuasive. Across all three stories, watch whether investigators move from a favorable biomarker to function people can feel—and whether tolerability survives the longer test.

Build the comparison before you build the stack

This week covered DD01 alongside semaglutide and tirzepatide, four GLP-1 agonists studied in Parkinson’s—exenatide, lixisenatide, liraglutide, and NLY01—and a PEGylated thymosin beta-4 construct that should not be confused with TB-500. That is exactly the kind of naming and mechanism overlap that makes an unstructured protocol hard to audit.

The BioStack Generator gives you one place to map the compounds you are considering against your actual goal, dosing schedule, overlapping pathways, and practical constraints. Use it to compare an incretin-centered metabolic plan with a thymosin beta-4/TB-500 recovery plan, then flag where the evidence belongs to a different molecule—such as DD01, NLY01, or PEG-rTβ4—rather than quietly treating every member of a class as interchangeable. It takes about two minutes, and the result is a cleaner set of questions to bring to your clinician.

Open the BioStack Generator →

Educational only. Investigational compounds discussed here are not approved for self-directed use, and this newsletter does not replace medical care.